{"analyses":[{"ciLowerLimit":"0.48","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.92","estimateComment":"T was the reference group in the estimation of the hazard ratio","groupIds":["OG000","OG001"],"nonInferiorityComment":"\\[not specified\\]","nonInferiorityType":"SUPERIORITY","pValue":"0.01","paramType":"Hazard Ratio (HR)","paramValue":"0.67","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.62","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.15","estimateComment":"T was the reference group in the estimation of hazard ratio","groupIds":["OG000","OG002"],"nonInferiorityComment":"\\[not specified\\]","nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"0.85"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"89.4","upperLimit":"93.2","value":"91.5"},{"groupId":"OG001","lowerLimit":"91.4","upperLimit":"94.8","value":"93.3"},{"groupId":"OG002","lowerLimit":"90.0","upperLimit":"93.7","value":"92.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1018"},{"groupId":"OG001","value":"1015"},{"groupId":"OG002","value":"1014"}],"units":"Participants"}],"description":"Estimated percentage of patients alive at 8 years from randomization, where overall survival is defined as the time from randomization to death from any cause; or censored at date last known alive.","dispersionType":"95% Confidence Interval","groups":[{"description":"Tamoxifen 20mg orally daily for 5 years\n\nLaboratory Biomarker Analysis: Correlative studies\n\nQuality-of-Life Assessment: Ancillary studies\n\nTamoxifen: Tamoxifen 20mg orally daily for 5 years","id":"OG000","title":"Tamoxifen"},{"description":"Tamoxifen 20mg orally daily for 5 years plus ovarian function suppression (OFS; triptorelin (GnRH analogue) 3.75 mg by im injection q28 days for 5 years; or surgical oophorectomy; or ovarian irradiation)\n\nLaboratory Biomarker Analysis: Correlative studies\n\nOophorectomy: Undergo bilateral surgical oophorectomy\n\nQuality-of-Life Assessment: Ancillary studies\n\nRadiation Therapy: Undergo ovarian irradiation\n\nTamoxifen: Tamoxifen 20mg orally daily for 5 years\n\nTriptorelin: 3.75 mg by im injection q28 days for 5 years","id":"OG001","title":"T+OFS"},{"description":"Exemestane 25mg orally daily for 5 years plus ovarian function suppression (OFS; triptorelin (GnRH analogue) 3.75 mg by im injection q28 days for 5 years; or surgical oophorectomy; or ovarian irradiation)\n\nExemestane: Exemestane 25mg orally daily for 5 years plus ovarian function suppression\n\nLaboratory Biomarker Analysis: Correlative studies\n\nOophorectomy: Undergo bilateral surgical oophorectomy\n\nQuality-of-Life Assessment: Ancillary studies\n\nRadiation Therapy: Undergo ovarian irradiation\n\nTriptorelin: 3.75 mg by im injection q28 days for 5 years","id":"OG002","title":"E+OFS"}],"paramType":"NUMBER","populationDescription":"Intention-to-treat","reportingStatus":"POSTED","timeFrame":"8-year estimates, reported at a median follow-up of 8 years","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"percentage of participants"}